Skip to main content
SpringerLink
Log in

Evolocumab cost effective in patients with HeFH

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Bulgarian lev

  2. equivalent to 7258 US dollars

Reference

  • Borissov B, et al. Cost-Effectiveness of Evolocumab in Treatment of Heterozygous Familial Hypercholesterolaemia in Bulgaria: Measuring Health Benefit by Effectively Treated Patient-Years (ETPY). 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCV63, 20 May 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/71463?pdfid=50137

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Evolocumab cost effective in patients with HeFH. PharmacoEcon Outcomes News 780, 15 (2017). https://doi.org/10.1007/s40274-017-4067-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4067-8

Search

Navigation